Login to Your Account

Cortex Dives After Agreeing To FDA Dosing Restrictions

By Aaron Lorenzo

Monday, October 30, 2006
FDA-imposed dosing limits are preventing Cortex Pharmaceuticals Inc. from more broadly studying CX717 in humans for now, causing the company's stock to lose more than a third of its value Friday, although the agency lifted a seven-month clinical hold on the drug in the process. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription